Abstract: Provided herein are prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer, autoimmune or an infectious disease.

Abstract: Provided herein are IL-21 prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.

Abstract: Provided herein are cytokine muteins and cytokine prodrugs and methods of making and using thereof.

Abstract: The present disclosure relates to prodrugs or chimeric molecules which comprise a carrier moiety, a cytokine moiety selected from an IL-10 agonist polypeptide and a TGF-? agonist polypeptide, and a masking moiety that binds to said cytokine moiety and inhibits its biological activity. Further included in the present disclosure are methods of making and using the novel prodrugs or chimeric molecules.

Abstract: Provided herein are interferon prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.

Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

Abstract: Provided herein are prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer, autoimmune or an infectious disease.

Abstract: The present application relates to novel prodrugs of IL-12. Further included in the present application are methods of making and using the novel prodrugs.

Abstract: The present disclosure provides novel isolated IL-2 fusion molecules that preferentially activate regulatory T cells (Treg) in vitro and in vivo. Further included are methods of making and using said novel fusion molecules to treat inflammatory and autoimmune diseases.

Abstract: Provided herein are IL-21 prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.

Abstract: Provided herein are cytokine muteins and cytokine prodrugs and methods of making and using thereof.

Abstract: Provided herein are IL-21 prodrugs and methods of making and using thereof for stimulating the immune system, or treating cancer or an infectious disease.

Abstract: Provided herein are IL-15 cytokine prodrugs and methods of making and using thereof.

Abstract: The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.

Abstract: The present invention provides fusion proteins comprising leptin and a second protein. The presence of the second protein provides increased biological activity and/or increased half-life in vivo. The present invention also provides human, canine and feline leptin molecules fused to peptides, antibodies or antibody fragments which enhances the abilities of the leptin molecules to transport through the blood-brain-barrier (BBB). The present invention also provides fusion proteins further comprising a peptide agonist that is capable of binding to and stimulate one, two or all three of the following receptors: GLP-1 receptor, Glucagon receptor, and GIP receptor. Also disclosed is a method of production such fusion proteins through recombinant technologies. The invention further discloses a pharmaceutical composition comprising one of the fusion proteins as an active intergradient as well as a method for using such a pharmaceutical composition to treat diseases in dogs, cats and humans.

Abstract: The present disclosure relates to heterodimeric fusion proteins comprising two polypeptides, the first polypeptide comprising a first peptide (P1), a linker (L1), and a Fc region (F1), the second polypeptide comprising a second peptide (P2), a linker (L2), and an Fc region (F2), wherein P1 and P2 are each independently selected from GLP-1, GLP-1 analogues, glucagon, glucacon analogues, GIP, GIP analogues, oxyntomodulin, oxyntomodulin analogues, exendin and exendin analogues; wherein F is selected from an IgG Fc, an IgA Fc, an IgE Fc, an IgGM Fc, and their analogues; wherein the C-terminals of the peptides are linked, though the Linker L, to the N-terminals of the Fc region F. In one embodiment, the fusion proteins disclosed herein have agonist activity against at least two of the GLP-1 receptor, the GIP receptor, and the glucagon receptor.

Abstract: The present specification discloses erythropoietin receptor agonists, compositions and medicaments comprising such erythropoietin receptor agonists, methods and uses for such erythropoietin receptor agonists and compositions and medicaments, and methods and uses for erythropoietin receptor agonists and compositions and medicaments for treating an anemia.